ClinicalTrials.gg
RecruitingNCT05558059Updated Oct 19, 2026

Imaging Retinal Vasculature in Infant Eyes

An observational study in Retinopathy of Prematurity, sponsored by Duke University. Recruiting at 2 sites in United States. Open to participants aged Up to 2 Months. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Duke University · Observational

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.
Updated Oct 19, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
16
Ages
Up to 2 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Retinopathy of Prematurity with a site in United States — 6 open to participants now, 10 under way, none of them phase 3. Retinopathy of Prematurity · United States.

Planned enrollment
14th of 15
16 · median 102
Started
2024
with 2 others
Observational
15 of 51
3 open now
Registered
44th of 51
by date
Lead sponsor
4 of 51
Duke University

Among the 51 studies in Retinopathy of Prematurity with a site in United States, this one is the 14th largest by planned enrollment of the 15 observational ones that give a count, is one of 3 that started in 2024, is one of 15 observational ones, and was the 44th registered.

Retinopathy of Prematurity

170 studies on the registry are indexed under Retinopathy of Prematurity; 28 are open to participants now.

Browse Retinopathy of Prematurity studies →

Open to participants now

6 of the 51 studies in Retinopathy of Prematurity with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 19 Retinopathy of Prematurity studies recruiting now, 7 (37%) set no upper age limit and 12 (63%) stop at 75 or younger; 19 take children under 18; 4 take healthy volunteers.

This study: Up to 2 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Retinopathy of Prematurity with a site in United States, or all of them as a file.
02

Study summary

Retinopathy of prematurity is a leading cause of childhood blindness worldwide. The fovea, a critical location in the retina determining visual acuity and visual function, and the blood vessels around it, are abnormally developed in infants with retinopathy of prematurity. However, how these blood vessels form during development of the human fovea remains unclear. This research will advance our understanding of the fundamental knowledge of how the blood vessels around the fovea form in infants, and how they change in diseased states such as preterm birth or retinopathy of prematurity.

03

Conditions studied

  • Retinopathy of Prematurity

Keywords

  • Retinopathy of Prematurity
  • Optical Coherence Tomography
  • Perifoveal vasculature
  • Vascular development
  • Macular edema
  • ROP
  • OCT
  • Prematurity
  • Optical Coherence Tomography Angiography
  • OCTA
04

Who can participate

Ages eligible
Up to 2 Months
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Preterm infants undergoing screening for retinopathy of prematurity

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Health care provider, knowledgeable of protocol, agrees that study personnel could contact the Parent/Legal guardian
  • Parent/Legal Guardian is able and willing to consent to study participation for the infant
  • Infant meets the American Association of Pediatrics eligibility of ROP screening, and is age less than 34 6/7 weeks postmenstrual age at first visit

Exclusion criteria

Exclusion Criteria:

  • Participant or Parent/Legal Guardian unwilling or unable to provide consent
  • Infant has a health or eye condition that preclude eye examination or retinal imaging (e.g. corneal opacity such as with Peter's anomaly or cataract)
  • Infant has a health condition, other than prematurity, that has a profound impact on brain development (e.g. anencephaly)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
16 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort 1

    16 preterm infants undergoing ROP screening to optimize methods to acquire and process beside infant perifoveal vascular imaging and assess rigor and reproducibility. The visits in the ICN (Intensive Care Nursery) will occur between 32 and 43 weeks post menstrual age at the time of ROP screening exams. Study visits will include, but are not limited to: * Ocular examination * OCT imaging of retinal microanatomy * OCTA imaging of retinal microvasculature * Medical and ocular history * Adverse event documentation

    Device: Handheld Optical Coherence Tomography with OCT Angiography

Interventions

  • DeviceHandheld Optical Coherence Tomography with OCT Angiography

    OCT systems are in vivo optical imaging technology that allows non-contact imaging of early-stage ocular pathology. They create real-time, non-invasive images of ocular microstructure and have become standard-of-care instruments in ophthalmic imaging in clinics and operating rooms. In contrast to the visible light used in clinical eye examinations, because infrared light is not visible, the participant is not disturbed by the light. OCT imaging allows the capture of hundreds of B-scan (cross-sectional) images in seconds. These B-scans are analyzed for depth-resolved information and can also be stacked to create a volume and the stack may be summed up to create a retinal image. OCT angiography (OCTA) is an extension of the OCT systems, by taking images at the same location over time to extract retinal vascular flow information. It has been utilized to assess the ocular blood flow in many adult and pediatric patients.

    Also known as: Handheld OCT and OCTA

06

What researchers measure

Primary outcomes

  1. Change in vascular density of intermediate and deep vascular plexus at the fovea and perifovea

    Measured by retinal OCTA imaging.

    Time frame: During hospitalization (at approximately 32-44 weeks post menstrual age, PMA)

Secondary outcomes

  1. Change in vascular density of superficial vascular plexus at the fovea and perifovea

    Measured by retinal OCTA imaging.

    Time frame: During hospitalization (at approximately 32-44 weeks post menstrual age, PMA)

  2. Change in avascular zone size of superficial, intermediate and deep vascular plexus

    Measured by retinal OCTA imaging.

    Time frame: During hospitalization (at approximately 32-44 weeks post menstrual age, PMA)

  3. Change in network length of intermediate and deep vascular plexus

    Vascular density of superficial vascular plexus at the fovea and perifovea; Avascular zone size of superficial, intermediate and deep vascular plexus; Network morphology of intermediate and deep vascular plexus; Network length of intermediate and deep vascular plexus.

    Time frame: During hospitalization (at approximately 32-44 weeks post menstrual age, PMA)

07

Study locations

1 of 2 sites recruiting
  • Duke University
    Durham, North Carolina 27710, United States
    Recruiting
    • Xi Chen, MD · Contactxi2.chen@duke.edu · (919) 684-8434
    • Michelle N McCall, MCAPM, BA · Contactmichelle.mccall@duke.edu · (919) 684-0544
    • Xi Chen, MD · Principal investigator
    • Cynthia A Toth, MD · Sub investigator
    • Sina Farsiu, PhD · Sub investigator
  • University of Pennsylvania
    Philadelphi, Pennsylvania 19104, United States
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The Elucidating Perifoveal Vascular Development in Infants study data cannot be analyzed for publication until they are released by the study Principal Investigator upon final review and approval by the Data Safety and Monitoring Committee. Data will be made available as follows: A summary, de-identified data set available upon request through direct inquiries to the Study PI or Statistical Analysis Center a year after publication. By the end of the funding period, de-identified SAS data sets and form images corresponding to all data collection forms, as well as key derived variables, will be put on file with a data repository. Researchers may request limited access data sets. The raw and analyzed imaging datasets will be made available after the completion of this study. Approved recipients will need to enter into a data sharing agreement. Costs for compilation and access to the datasets will be the responsibility of the recipients.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be made available after the completion of the study.

Access criteria: Data requests must be submitted to the PI or the Statistical Analysis Center. Approved recipients will need to enter into a data sharing agreement. Costs for compilation and access to the datasets will be the responsibility of the recipients.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Aug 2027, 34 months after the start.

Of 26 observational studies under Retinopathy of Prematurity, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 53. This study's planned 34 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2022
First posted
Sep 28, 2022
StartActual
Oct 3, 2024
Primary completionEst.
Aug 31, 2027
CompletionEst.
Aug 31, 2027
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • University of Pennsylvania · Philadelphi, United States
Show 1 removed
  • University of Pennsylvania · Philadelphia, United States
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    1 site added, 1 site removed
    Show site
    • University of Pennsylvania · Philadelphi, United States
    Show 1 removed
    • University of Pennsylvania · Philadelphia, United States
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05558059
Lead sponsor
Duke University
Responsible party
Sponsor
First posted
Sep 28, 2022
Start date
Oct 3, 2024
Primary completion
Aug 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Oct 19, 2026

Study contacts

Xi Chen, MD
Contact
xi2.chen@duke.edu
(919) 684-8434
Michelle N McCall
Contact
michelle.mccall@duke.edu
(919) 684-0544
Xi Chen, MD
principal investigator · Duke University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion